PO.PS01.03 · 人群科学
转录组和SNP分析揭示结直肠癌中的早发性和种族相关性特征
Transcriptomic and SNP profiling reveals early-onset and ethnicity-associated signatures in colorectal cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
结直肠癌(CRC)是美国致死率第二高的癌症,在过去十年中早发性(年龄 < 50岁)病例显著上升。尽管早期(I/II期)CRC可治疗且生存率较高,但这些肿瘤往往预后不良,尤其是在西班牙裔等少数族群中。西班牙裔发生晚期(III/IV期)诊断的比例高于非西班牙裔白人(NHW),提示遗传和非遗传因素均可能促成这一差异。为识别早发性和种族相关性差异的潜在生物学因素,我们研究了可能改善筛查和预后的转录组学和基因型生物标志物。我们对来自西班牙裔和NHW患者的CRC组织和肿瘤旁正常组织(NAT)进行了RNA测序。使用两个独立的流程——Rsubread和Salmon——获得基因水平定量。DESeq2分析在CRC和NAT样本之间识别出两种工具共有的996个差异表达基因(DEG,log2倍数变化 ≥ 2.0和 ≤ -2.0,错误发现率0.05)。在各种族队列内分析时,西班牙裔中识别出1251个DEG,NHW中识别出899个。值得注意的是,在西班牙裔组内,与NHW相比,早发性和晚期西班牙裔CRC样本之间有311个共有的DEG。使用Ingenuity Pathway Analysis和基因集富集分析进行的通路富集分析揭示了细胞周期调控通路的显著失调,包括有丝分裂G2-G2/M期、有丝分裂G1期和G1/S转换,以及细胞周期检查点,这些通路对凋亡和肿瘤进展至关重要。相互作用分析进一步揭示138个DEG(log2倍数变化 ≥ 1.0和 ≤ -1.0,p值 ≤ 0.05)与西班牙裔队列中CRC的发生显著相关。此外,使用Genome Analysis Toolkit(GATK)和Snpeff工作流进行的变异发现和注释,识别出383个西班牙裔CRC样本中独有或富集且预测具有高或中等功能影响的变异。其中,SNP相关基因分析显示携带rs10614变异的NCF1下调与西班牙裔CRC队列中的肿瘤状态显著相关。NCF1表达降低与ROS缺乏诱导的结肠炎介导的肿瘤发生相关。总体而言,我们的研究结果揭示了可能构成CRC差异基础的西班牙裔特异性转录组学和基因型特征,并识别出可改善筛查的潜在生物标志物。在西班牙裔患者组织和患者来源类器官模型中的进一步功能研究将有助于阐明这些基因和变异的生物学作用,最终促进针对高风险人群的早期筛查策略和靶向治疗的开发。
查看英文原文 English abstract
Colorectal cancer (CRC) is the second deadliest cancer in the United States, with early-onset (age < 50) cases rising significantly over the past decade. Although early-stage (I/II) CRC is treatable with a higher survival rate, these tumors often present with poor outcomes, particularly among minority groups like Hispanics. Hispanics experience higher rates of late-stage (III/IV) diagnosis than Non-Hispanic Whites (NHW), suggesting that both genetic and non-genetic factors may contribute to this disparity. To identify potential biological contributors to early-onset and ethnicity-associated disparities, we investigated transcriptomic and genotypic biomarkers that may improve screening and prognosis. We performed RNA sequencing on CRC tissues and normal tissues adjacent to the tumor (NATs) from Hispanic and NHW patients. Gene level quantification was obtained using two independent pipelines - Rsubread and Salmon. DESeq2 analysis, identified 996 differentially expressed genes (DEGs, log2 foldchange ≥ 2.0 and ≤ -2.0 and a false discovery rate of 0.05) common to both the tools between CRC and NAT samples. When analyzed within each ethnic cohort 1251 DEGs were identified in Hispanics and 899 in NHWs. Notably, within the Hispanic group, 311 DEGs were common between early-onset and late-stage Hispanic CRC samples compared to NHWs. Pathway enrichment analyses using Ingenuity Pathway Analysis and Gene Set Enrichment Analysis revealed significant dysregulation of the cell cycle regulatory pathways including the Mitotic G2-G2/M phases, Mitotic G1 phase and G1/S transition, as well as Cell cycle checkpoints, pathways critical for apoptosis, and tumor progression. Interaction analysis further revealed 138 DEGs (log2 foldchange ≥ 1.0 and ≤ -1.0 and p- value ≤ 0.05) display a significant association with CRC occurrence in the Hispanic cohort. Additionally, variant discovery and annotation using the Genome Analysis Toolkit (GATK) and Snpeff workflows, identified 383 variants either unique to or abundant in Hispanic CRC samples and predicted to have high or moderate functional impact. Among these, analysis of SNP-associated genes revealed that the downregulation of NCF1, carrying the rs10614 variant, was significantly correlated with tumor status in the Hispanic CRC cohort. Reduced NCF1 expression is associated with ROS deficiency induced colitis-mediated tumorigenesis. Overall, our findings reveal Hispanic-specific transcriptomic and genotypic signatures that may underlie CRC disparities and identify potential biomarkers for improved screening. Further functional studies in Hispanic patient tissues and patient-derived organoid models will help elucidate the biological roles of these genes and variants, ultimately promoting the development of early-screening strategies and targeted therapies for high-risk populations.
利益披露 Disclosure
S. Nair, None..
B. Huang, None..
U. Tania, None..
B. Grajeda, None..
M. Schatz, None..
R. McCoy, None.